Products Cited in Publications Worldwide Ruthenium (II)–arene complexes with chelating quinoline ligands as anti-amyloid agents

Ruthenium (II)–arene complexes with chelating quinoline ligands as anti-amyloid agents

Meiss, Cade J; Bothwell, Paige J; Webb, Michael I

DOI:

Abstract

Recent recognition of the soluble form of the amyloid-beta (Ab) peptide as a neurotoxic agent in Alzheimer’sdis ease (AD) has spurred the development of agents to target this species. Because Ab is known to chelate metal ions in solu tion, metal-based therapeutics are uniquely suited to exploit this affinity, where coordination to Ab has been shown to impact the neurotoxicity of the peptide. Ruthenium(II)–arene complexes are unique candidates for evaluation, as one face ofthemoleculeisblockedbythehydrophobicarenering,whilecoordinationtotheAb peptide can occur on the other side of the molecule. We have prepared and evaluated two Ru(II)–arene complexes with chelating quinoline-based ligands, Ru1 and Ru2, for their respective anti-amyloid abilities. Although both complexes decreased the aggregation of soluble Ab, Ru1 displayed promise in disrupting formed aggregates of the peptide. These findings represent an exciting new avenue for therapeutic development in AD, where both sides of the aggregation equilibrium are affected.

Keywords

Alzheimer’s disease ; amyloid-beta ; ruthenium(II) therapeutics ; peptide aggregation

Purchased from AmBeed

8-Aminoquinoline

A104160578-66-597%

8-Aminoquinoline

143.0/100g

Detail